Bromantane
Energy, Anti-fatigue
Elimination half-life reported at 11.21 h in humans.
In short
- A Russian adamantane derivative classed as an actoprotector — intended to sustain performance under fatigue.
- Elimination half-life reported at about 11 hours in humans, which is real pharmacokinetic data.
- Unusual profile: combines mild stimulant-like effects with anxiolytic ones, rather than the anxiety typical of stimulants.
- Explicitly named on the WADA Prohibited List — it has caused actual doping violations.
- Registered in Russia; not approved in the US, EU, or UK.
Structure
How it works
Bromantane is proposed to work by upregulating dopamine synthesis rather than by releasing or blocking reuptake of existing dopamine. Studies report increased expression of tyrosine hydroxylase and aromatic L-amino acid decarboxylase, the rate-limiting enzymes in dopamine production.
This mechanism is the usual explanation for its unusual profile: because it increases synthesis rather than forcing release, it does not produce the depletion, crash, or tolerance pattern typical of conventional stimulants, and it does not carry their anxiogenic effect.
Effects on GABAergic and serotonergic signalling have also been described and are proposed to underlie the anxiolytic component.
What the research shows
Russian clinical studies report reduced fatigue, improved physical work capacity, and anxiolytic effects in asthenic conditions.
It was used by Russian athletes, which is how it came to WADA's attention and was subsequently banned — that history is itself indirect evidence that it does something to performance.
No independent Western clinical replication exists.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Human — Russian clinical use for asthenia | 50–100 mg daily | oral | PubMed |
| Human — pharmacokinetics | Elimination half-life approximately 11.2 h | oral | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported, often intermittently | 50–100 mg, not daily | oral |
Community and registered clinical doses coincide here. Intermittent rather than daily use is commonly described on the basis that the dopaminergic upregulation persists beyond the dosing day, though this is reasoned rather than demonstrated.
Handling and storage
Oral, as capsules or powder. Reported to be fat-soluble, so administration with food is sometimes described for absorption.
Given the ~11 hour half-life, morning dosing is the usual pattern to limit sleep disruption.
Side effects
Reported as well tolerated in Russian clinical use, which is the bulk of the safety data.
Community reports mention insomnia if dosed late, irritability, and headache.
Independent long-term safety data outside Russia does not exist. The dopaminergic mechanism raises theoretical questions about chronic use that have not been studied.
Combinations
No formal interaction data. The dopaminergic mechanism makes combination with other dopaminergic agents — stimulants, MAO inhibitors, dopamine agonists — the theoretically relevant caution.
Particularly worth noting alongside 9-Me-BC, which is also dopaminergic and additionally an MAO inhibitor.
Research status
Developed in the Soviet Union in the 1980s, with published Russian work on actoprotective and anxiolytic effects and on the dopamine synthesis mechanism.
Western independent research is minimal. Most accessible information derives from Russian publications and from anti-doping literature.
Legal status
Registered as a medicine in Russia. Not approved in the US, EU, UK, Canada, or Australia. Sold in Western markets as a research chemical.
WADA status
PROHIBITED. Bromantane is explicitly named on the WADA Prohibited List under S6 (stimulants). It was added following its use by Russian athletes at the 1996 Olympics and has produced actual sanctions. This is not an inference from S0 — it is named.
Conclusion
Bromantane is one of the few compounds in this section with a plausible mechanism, real human pharmacokinetics, and a registered clinical use somewhere.
It is also explicitly banned in sport, with a documented history of sanctions. For anyone tested, that is the beginning and end of the analysis.
Sources
Track your own Bromantane protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.